Home > News > featured news > The top 20 drugs by 2018 U.S. sales

The top 20 drugs by 2018 U.S. sales

fiercepharma | June 17, 2019

Take a look at most global drugmakers income statements, and its obvious the U.S. is all important for pharma. Sales in the country typically outshine those in other regions. And its no wonder: The U.S. is a $485 billion market, according to IQVIA's latest report on the global drug industry. That size opportunity is one reason the U.S. is the first place most drugs launch. But the U.S. is also where drugmakers have the most pricing power, and where regulators, for all the criticism they face for any delays, tend to speed worthy new treatments to market. And these days, when many of the world's biggest drugs are also biologics, the U.S. is also where top brands face less copycat competition. While biosimilars overseas are seriously eating into sales for several big brands—including AbbVie's behemoth Humira—in the U.S., patent protections have kept many biosims at bay. That's certainly the case for Humira, which now won't face U.S. biosims until 2023, thanks to AbbVie's series of patent settlements with its potential rivals. Check out the list below, and you'll notice several major blockbusters benefiting from biosimilar delays. You'll also see some small-molecule meds that are about to fall hard to generic competition. Overall, the assortment of drugs spans specialty fields such as cancer and immunology, and mass-market indications such as diabetes. In general, the top of the list is a lineup of successful legacy drugs, including Humira, Celgene's Revlimid (No. 2), Amgen's Enbrel (No. 3) and Roche's Rituxan (No. 4). But driven by successful launches for some precocious challengers—and a mix of generic competition, tighter discounts and slow growth for older blockbusters—a few newbies are quickly moving up the rankings.

Spotlight

Radiopharmaceutics

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs which have radioactivity. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

More featured news

Spotlight

Radiopharmaceutics

Related News

Ultragenyx Pharmaceutical Inc Announces U.S. FDA Approval of Dojolvi™ For The Treatment of Long-Chain Fatty Acid Oxidation Disorders

Ultragenyx | July 03, 2020

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life-threatening genetic disorders in which the body is unable to convert long-chain fatty acids into energy. Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with LC-FAOD. “With today’s FDA approval, patients living with this serious, unpredictable, and often catastrophic disease now have an approved therapy. Many patients with long-chain fatty acid oxidation disorders have difficult lives with frequent hospitalizations and major medical events despite the best current care. Now these patients have an approved treatment as an option to help manage their disease,” said Camille L. Bedrosian, M.D., Chief Medical Officer of Ultragenyx. “We are grateful to the patients, caregivers, families, dietitians and doctors involved for helping to make this community milestone possible, and we are committed to ensuring that all patients in the U.S. with LC-FAOD who might benefit from Dojolvi will have access to it.”

Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan

Fiercepharma | June 18, 2020

In the high-stakes patent fight between Biogen and Mylan over Tecfidera’s main remaining patent, Mylan has scored a major win in federal court. U.S. District Judge Irene Keeley said Mylan “demonstrated by clear and convincing evidence” that certain claims of Biogen’s '514 patent are invalid for “lack of written description.” The decision threatens Biogen’s bestselling medicine with early generics; Tecfidera, a multiple sclerosis drug, generated $3.3 billion in the U.S. last year. The company's '514 patent is set to expire in 2028, meaning the decision, if upheld, could wipe out years of monopoly sales. Biogen’s shares were down about 6% on Thursday morning on the news. A spokesman said the company is disappointed with the decision and will appeal.

In the World of Big Pharma, an Italian Oral Spray Survives

Dr ZinX | July 10, 2020

Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide." Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplementation may contribute to faster recovery from viral illness by directly inhibiting viral replication at the protein level. In order for Zinc to cross into our cells and operate a special transport system is required. This system includes zinc ionophores and zinc binding-proteins. The list of zinc ionophores is extensive and includes Hinokitiol, hydroxychloroquine, quercetin, epigallocatechin, pyrithione, zincophorin, and others.